Research programme: cancer therapeutics - Abraxis BioScience

Drug Profile

Research programme: cancer therapeutics - Abraxis BioScience

Alternative Names: ABI-010; ABI-013; ABI-139; nab®-17AAG; nab®-ABI-139; nab®-CY196; NBT-010

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abraxis BioScience
  • Developer Celgene Corporation
  • Class Albumins; Antisense oligonucleotides; Taxanes
  • Mechanism of Action Antisense RNA inhibitors; HSP90 heat-shock protein inhibitors; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
  • 13 Jan 2014 ABI 010 (NBT 010) licensed to NantBioScience
  • 16 Oct 2010 Abraxis BioScience has been acquired by Celgene Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top